The QT interval and the atypical antipsychotic, sertindole
AbstractSertindole is a limbic-selective antipsychotic agent with a strong affinity for D 2 , 5-HT 2 and α 1 -adrenergic receptors. Prolongation of the QT interval and other adverse cardiac or cardiovascular reactions are known effects of most antipsychotic drugs. For this reason such effects have been extensively monitored during clinical trials of sertindole. A small proportion of sertindole-treated patients were found to exhibit an increase in QT interval. Detailed analysis revealed no increased risk with sertindole of lethal complications due to an increase in QT interval. Nevertheless, as with other antipsychotics, electrocardiogram (ECG) recordings should be made prior to starting and during treatment with sertindole.